The objective of this proposal is to develop the Operations, Biostatistics and Data Management Center (OBDMC) and infrastructure to support the Pediatric Brain Tumor Clinical Trials Consortium (PBTCTC) for the expeditious evaluation of new therapeutic approaches in children with central nervous system (CNS) tumors. The Consortium of eight Participant Member Institutions is expected to recruit 80-100 patients each year to 3-4 clinical trials. The primary objective of the Consortium is to improve the therapeutic outcome for children with CNS tumors through the conduct of phase I, II and pilot clinical trials and preliminary correlative laboratory investigations. The trials will evaluate innovative and technically challenging therapies and diagnostic procedures. The role of the Operations, Statistics and Data Management Center in achieving this objective includes: 1. Coordinating protocol development and management including amendments and status changes (opening, suspension, closures, etc.) And circulating protocols and amendments to Participant Member Institutions and the NCI. 2. Providing sound statistical science to the Consortium for the design and analysis of clinical trials and for the timely reporting of findings. 3. Designing and developing a distributed data management (DDM) system to ensure accurate and timely acquisition of study data consistent with study designs and objectives while providing a secure system for the electronic collection and storage of Consortium information. The following subsidiary tasks will be performed: 4. Implementing procedures to meet all regulatory reporting requirements. 5. Administering laboratory correlative studies, including coordination and support for the acquisition and shipping of specimens and data; as well as coordination and tracking of banked tissue in a virtual brain tumor tissue bank.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA081457-01S1
Application #
6254999
Study Section
Special Emphasis Panel (ZCA1 (J2))
Project Start
1999-04-01
Project End
2004-03-31
Budget Start
2000-01-01
Budget End
2000-03-31
Support Year
1
Fiscal Year
2000
Total Cost
$16,413
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Kilburn, Lindsay B; Kocak, Mehmet; Baxter, Patricia et al. (2018) A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 65:
Banerjee, Anuradha; Jakacki, Regina I; Onar-Thomas, Arzu et al. (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19:1135-1144
Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314
Gururangan, Sridharan; Reap, Elizabeth; Schmittling, Robert et al. (2017) Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). Cancer Immunol Immunother 66:1589-1595
Zukotynski, Katherine A; Vajapeyam, Sridhar; Fahey, Frederic H et al. (2017) Correlation of18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med 58:1264-1269
Poussaint, Tina Young; Vajapeyam, Sridhar; Ricci, Kelsey I et al. (2016) Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 18:725-34
Salloum, Ralph; Hummel, Trent R; Kumar, Shiva Senthil et al. (2016) A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol 129:443-451
Han, Kelong; Peyret, Thomas; Quartino, Angelica et al. (2016) Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 81:148-60
Kilburn, Lindsay B; Kocak, Mehmet; Decker, Rodney L et al. (2015) A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol 17:303-11
Packer, Roger J; Rood, Brian R; Turner, David C et al. (2015) Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol 121:217-24

Showing the most recent 10 out of 65 publications